Tag Archives: Drug

Lilly scores FDA nod for new migraine drug Reyvow

Eli Lilly is already working to grow market share for its migraine prevention med Emgality, but now the company has a new medicine to add to its suite.  The drugmaker Friday won approval for Reyvow for the acute treatment of migraines as they occur. The drug, formerly known as lasmiditan, becomes the latest launch in Lilly’s pain and migraine franchise, which it bolstered… Read More »

Viewpoints: Drug Industry Was Allowed To Hijack Policymaking That Led To Opioid Epidemic; Build On The ACA To Reach Dream Of Universal Health Care

Opinion writers weigh in on these health topics and others. The Washington Post: The Real Scandal Of The Opioid Crisis: Crony Capitalism Justice Department Inspector General Michael E. Horowitz issued a grim account this week of the Drug Enforcement Administration’s slow response to the opioid crisis and failure to use all the tools at its… Read More »

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

(Reuters) – A U.S. judge on Friday upheld two patents relating to Amgen Inc’s blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California in this October 21, 2013 file… Read More »

Senate advances drug pricing bill, setting up September vote

Dive Brief: Legislation limiting drug price increases in Medicare will face a full Senate debate in September after the Finance Committee approved it on a mixed vote Thursday. The bill could see some modification before then to incorporate additional proposals, potentially including a ban on rebates to payers. In addition, House Democrats are working on… Read More »

Relatively Unknown Secret Committees Have Been Influencing Insurers’ Drug Coverage Decisions For Decades

News outlets report on stories related to pharmaceutical pricing. Reuters: The Obscure Advisory Committees At The Heart Of The U.S. Drug Pricing Debate Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries. Priced around $ 7,000 each, the drugmakers called… Read More »